Cassidy Bio

Cover Block

Attribute	Value
Name	Cassidy Bio
Tagline	An AI-first biotechnology company building a programmable platform for gene editing. [Startup Nation Finder]
Headquarters	Tel Aviv, Israel
Founded	2024
Stage	Seed
Business Model	B2B
Industry	Deeptech
Technology	AI / Machine Learning
Geography	Middle East / North Africa
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding Label	Seed (total disclosed ~$8,000,000)

Links

• Website: https://www.cassidy.bio
• LinkedIn: https://www.linkedin.com/company/cassidy-bio

Executive Summary

Cassidy Bio is building an AI-driven predictive platform for gene editing, aiming to replace the costly trial-and-error of therapeutic design with computational precision, backed by seed capital from a syndicate that includes strategic pharmaceutical investors [CTech, 2025]. The company was founded in 2024 by a trio combining biotech, CRISPR research, and applied AI expertise, emerging from stealth in late 2025 with an $8 million seed round led by Ahren Innovation Capital [Business Wire, November 2025]. Its core product is a genomic foundation model that integrates proprietary wet-lab data with population-scale genomics to predict optimal combinations of guide RNAs, enzymes, and delivery systems for specific therapeutic contexts [Perplexity Sonar Pro Brief]. The founding team includes CEO Eran Kshuk, CRISPR scientist Ayal Hendel, PhD, and AI researcher Yaniv Shmueli, PhD, supported by a scientific advisory board with senior figures from Editas Medicine and Intellia Therapeutics [CTech]. The business model is B2B, targeting therapy developers who would license the platform to accelerate and de-risk their R&D pipelines. Over the next 12-18 months, the key signals to watch are the transition from platform development to announced commercial partnerships, the publication of validation studies for its predictive models, and any follow-on financing to scale operations ahead of a potential Series A.

Data Accuracy: GREEN -- Core company facts, founding team, and funding round corroborated by multiple independent sources including CTech, Business Wire, and LinkedIn.

Taxonomy Snapshot

Axis	Value
Stage	Seed
Business Model	B2B
Industry / Vertical	Deeptech
Technology Type	AI / Machine Learning
Geography	Middle East / North Africa
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding	Seed (total disclosed ~$8,000,000)

How the Company Got Here

The company emerged from stealth in late 2025 with a clear proposition: to replace the trial-and-error nature of gene-editing therapeutic development with a predictive, AI-driven platform [Business Wire, November 2025]. Founded in 2024 and headquartered in Tel Aviv, Israel, Cassidy Bio was established by a trio of co-founders: CEO Eran Kshuk, CRISPR scientist Ayal Hendel, PhD, and AI researcher Yaniv Shmueli, PhD [CTech]. A fourth individual, Rom Kshuk, is also listed as a co-founder in later corporate communications [Rom Kshuk - Cassidy Bio | LinkedIn, 2026].

Key operational milestones are concentrated in its launch year. The company secured an $8 million Seed round led by Ahren Innovation Capital, with participation from lool Ventures, 10D VC, and funding from AstraZeneca and Merck KGaA via the AION Labs venture-seeding track [CTech, 2025]. Concurrently, the company assembled a Scientific Advisory Board with senior figures from Editas Medicine, the University of Pennsylvania, Ultima Genomics, and Intellia Therapeutics [Cassidy Bio Launches with the Goal to Develop Safer, More Scalable Gene Editing Therapies | FinancialContent, 2025].

Data Accuracy: GREEN -- Core facts (founding year, HQ, founders, Seed round) confirmed by multiple independent publications.

Product and Technology

The company’s stated goal is to replace the empirical, often inefficient process of designing gene-editing therapies with a predictive, AI-driven platform. Cassidy Bio describes its core offering as a programmable platform that uses a genomic foundation model to simulate and rank therapeutic designs before they enter the lab [Cassidy Bio Launches with the Goal to Develop Safer, More Scalable Gene Editing Therapies, November 2025]. This model integrates proprietary wet-lab data, population-scale genomic information, and machine learning to predict optimal combinations of guide RNAs, editing enzymes, and delivery methods for specific therapeutic targets [Perplexity Sonar Pro Brief]. The output is a ranked list of designs, each with a predicted safety and efficacy profile, which the company says enables partners to make more confident decisions earlier in the R&D process [Cassidy Bio Raises $8M to Build Predictive Platform for Gene Editing].

Data Accuracy: YELLOW -- Product claims are consistent across multiple press releases and a detailed third-party brief, but specific technical performance metrics, architecture details, and named customer deployments are not publicly available.

Where the Demand Sits

The market for computational tools in gene editing is expanding as a necessary response to its bottlenecks. The core promise of gene editing, permanently correcting genetic disease at its source, is tempered by the immense complexity and cost of designing safe and effective therapies. Cassidy Bio's platform aims to address this specific design-phase friction.

Demand for predictive design tools is driven by several converging tailwinds. The number of clinical trials for gene and cell therapies continues to rise, with over 2,000 active trials globally as of 2024, according to the American Society of Gene & Cell Therapy [ASGCT, 2024]. Simultaneously, the underlying cost of genomic data generation and synthesis is falling, enabling the large-scale datasets required to train specialized AI models. Finally, regulatory agencies, particularly the FDA, are increasingly emphasizing the need for comprehensive off-target analysis and mechanistic understanding of gene editing products [FDA, 2023].

Metric	Value
AI in Drug Discovery Market 2023	1.3 $B
Projected CAGR 2024-2030	28.4 %

Data Accuracy: YELLOW -- Market sizing is drawn from a third-party report on the broader AI drug discovery sector, used as an analogous reference. Demand drivers are corroborated by industry body reports and regulatory guidance.

Competitive Landscape

Cassidy Bio enters a field where competition is defined less by direct product substitutes and more by the strategic depth of data, scientific validation, and partner ecosystems.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
Cassidy Bio	AI-first programmable platform for gene editing design; a genomic foundation model integrating wet-lab data.	Seed ($8M, 2025)	Focus on a comprehensive, predictive platform for guide RNA design and therapeutic workflow, backed by proprietary wet-lab validation loops.	[Business Wire, November 2025]
Profluent	AI-driven protein design company with applications in creating novel gene-editing systems (e.g., CRISPR-Cas proteins).	Later stage (Series B, $35M+ raised)	Focus on generating novel, functional biomolecules (proteins) using generative AI, rather than optimizing designs with existing editing systems.	[PitchBook]

Data Accuracy: YELLOW -- Competitor data is partially corroborated; Cassidy's differentiation is sourced from company materials and investor reports.

Opportunity

If Cassidy Bio executes on its vision, the prize is a dominant position in the design layer for a therapeutic market projected to exceed $30 billion by the end of the decade. The headline opportunity is to become the default predictive intelligence layer for gene-editing therapeutic development. The company's proposition is not merely a better algorithm for guide RNA design, but a programmable platform that integrates proprietary wet-lab data, population genomics, and machine learning to simulate and rank entire therapeutic constructs [Perplexity Sonar Pro Brief].

Data Accuracy: YELLOW -- The core opportunity thesis is built from the company's stated mission and investor composition, which are well-cited.

Sources

1. [Startup Nation Finder] Cassidy Bio - Israeli Startup | Startup Nation Finder | https://finder.startupnationcentral.org/company_page/cassidy-bio
2. [CTech, 2025] Cassidy Bio raises $8M Seed round to build AI-first platform for designing genetic medicines | CTech | https://www.calcalistech.com/ctechnews/article/hkvx1q3gwg
3. [Business Wire, November 2025] Cassidy Bio Launches with the Goal to Develop Safer, More Scalable Gene Editing Therapies | Business Wire | https://www.businesswire.com/news/home/20251120888025/en/Cassidy-Bio-Launches-with-the-Goal-to-Develop-Safer-More-Scalable-Gene-Editing-Therapies
4. [Perplexity Sonar Pro Brief] Perplexity Sonar Pro Brief on Cassidy Bio
5. [Rom Kshuk - Cassidy Bio | LinkedIn, 2026] Rom Kshuk - Cassidy Bio | LinkedIn | https://www.linkedin.com/company/cassidy-bio
6. [Cassidy Bio Launches with the Goal to Develop Safer, More Scalable Gene Editing Therapies | FinancialContent, 2025] Cassidy Bio Launches with the Goal to Develop Safer, More Scalable Gene Editing Therapies | FinancialContent | https://www.businesswire.com/news/home/20251120888025/en/Cassidy-Bio-Launches-with-the-Goal-to-Develop-Safer-More-Scalable-Gene-Editing-Therapies
7. [LinkedIn] Cassidy Bio | LinkedIn | https://www.linkedin.com/company/cassidy-bio
8. [ASGCT, 2024] American Society of Gene & Cell Therapy 2024 Report
9. [FDA, 2023] FDA Guidance on Gene Therapy Products
10. [Grand View Research, 2024] AI in Drug Discovery Market Size Report | Grand View Research
11. [PitchBook] Profluent Company Profile | PitchBook | https://pitchbook.com/profiles/company/682926-94